Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for AC Immune (ACIU) over the last 11 years, with Q3 2025 value amounting to -$317518.9.

  • AC Immune's Cash from Financing Activities fell 5901.56% to -$317518.9 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 10249.51%. This contributed to the annual value of -$1.3 million for FY2024, which is 10262.21% down from last year.
  • As of Q3 2025, AC Immune's Cash from Financing Activities stood at -$317518.9, which was down 5901.56% from -$298348.9 recorded in Q2 2025.
  • Over the past 5 years, AC Immune's Cash from Financing Activities peaked at $46.3 million during Q4 2023, and registered a low of -$991852.6 during Q1 2022.
  • For the 5-year period, AC Immune's Cash from Financing Activities averaged around $4.7 million, with its median value being -$147034.8 (2022).
  • Per our database at Business Quant, AC Immune's Cash from Financing Activities plummeted by 58268.44% in 2022 and then surged by 2960920.12% in 2023.
  • Quarter analysis of 5 years shows AC Immune's Cash from Financing Activities stood at $31.2 million in 2021, then plummeted by 100.5% to -$156741.3 in 2022, then skyrocketed by 29609.2% to $46.3 million in 2023, then plummeted by 100.49% to -$224879.8 in 2024, then crashed by 41.19% to -$317518.9 in 2025.
  • Its Cash from Financing Activities was -$317518.9 in Q3 2025, compared to -$298348.9 in Q2 2025 and -$286960.6 in Q1 2025.